Normal Neurodevelopmental Outcomes in PNPO Deficiency: A Case Series and Literature Review

Area of Science:

• Biochemistry
• Genetics
• Neonatal Medicine

Background:

• Pyridox(am)ine 5 -phosphate oxidase deficiency causes severe neonatal encephalopathy.
• This rare condition can be fatal if not treated promptly and may mimic hypoxic ischemic encephalopathy.
• Diagnosis and treatment are often delayed due to its rarity and overlapping symptoms.

Purpose of the Study:

• To report cases of pyridox(am)ine 5 -phosphate oxidase deficiency.
• To highlight the impact of early diagnosis and treatment on neurodevelopment.
• To advocate for a lower threshold for investigating and treating this deficiency.

Main Methods:

• Case series reporting four patients with pyridox(am)ine 5 -phosphate oxidase deficiency.
• Description of treatment with pyridoxal-5 -phosphate.
• Follow-up on neurodevelopmental outcomes.

Main Results:

• Three patients treated within the first few days of life, one within the first month.
• One sibling received elective treatment from birth.
• Early diagnosis and treatment were associated with normal childhood neurodevelopment.

Conclusions:

• Early diagnosis and treatment of pyridox(am)ine 5 -phosphate oxidase deficiency are critical for favorable neurodevelopmental outcomes.
• A high index of suspicion and prompt initiation of pyridoxal-5 -phosphate are recommended for neonates with unexplained encephalopathy.
• Consideration for this diagnosis should be given even in cases of presumed hypoxic ischemic encephalopathy.